In Vitro Study Articles & Analysis
23 news found
Based on these properties, PDMS has been used in a wide range of applications such as micropumps, catheter surfaces, dressings and bandages, microvalves, optical systems, in vitro disease studies, implants, microfluidics, and photonics. In addition, PDMS is the most widely used material for the manufacture of microfluidic devices, which are an important ...
This critical step in the drug development process refers to the systematic evaluation of the safety of therapeutic drugs through laboratory studies and animals in vitro. Alfa Chemistry has established a drug safety evaluation system that meets international standards, helping clients to shorten the experimental time and reduce the cost as well. ...
This formulation (Bupigel) prolonged bupivacaine release from the formulation in dissolution-like studies in vitro and analgesia in vivo in mouse, rat, and pig models. In this study we assessed Bupigel neurotoxicity on rabbit sciatic nerve using histopathology and electrophysiologic testing. Sciatic nerves of both hind limbs were injected ...
” At the meetings, the company presented data from IND-enabling studies demonstrating the safety and pharmacokinetic profile of OLX-07010 in in vitro and in vivo preclinical studies. In multiple animal species, OLX-07010, a novel small molecule inhibitor of tau self-association, demonstrated good oral bioavailability, with no significant ...
A research team in Zurich, Switzerland has presented results from an in vitro study showing that photodisinfection achieved >99.99% eradication (4-7 log10 kill) of the key pathogens in biofilms associated with implantable joint infections, with no reported regrowth. ...
(LON: OBI), this week presented an in vitro study at the World Anti-Microbial Resistance Congress, in Maryland, USA on the effectiveness of its photodisinfection technology against the group of highly infectious and antibiotic-resistant bacteria known as ESKAPE pathogens.[i] ESKAPE pathogens are the most virulent and dangerous pathogens responsible for some of ...
Presentation highlights: Araris’ anti-Nectin-4 antibody-drug conjugate (ADC) showed superior activity to enfortumabvedotin (Padcev®, EV) in head-to-head in vitro and in vivo studies Araris’ linker technology was used to generate a highly homogenous and pure ADC within 24 hours with enfortumab as the targeting antibody and monomethyl auristatin ...
Following the successful completion of the R&D project in 30th September 2016 (supported by a Smart award from the Innovate UK (TSB), Arterius has recently been awarded further funding from the Biomedical Catalyst-Early Stage programme to conduct the In-vitro and In-vivo GLP Evaluation of the Novel Bioresorbable Coronary Scaffolds; ArterioSorb. ...
“We are pleased to be supported by the US Navy and MTEC and are working closely with them to advance our topical pravibismane through phase 2 proof-of-concept studies,” said Karim Lalji, CEO of Microbion Pharma Corp. “Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and ...
Darker pigmentation observed may be a sign of multi-functional cystinosin activity post gene therapy Patients with cystinosis frequently exhibit blond or lighter-colored hair and fair complexion because of reduced levels of melanin in their skin. In vitro studies have demonstrated that cystinosin is located in melanosomes of melanocytes and when functional ...
The newly introduced antigens consist of five of the most common staphylococcus aureus enterotoxins and are ideal for in vitro detection and diagnostic studies. Staphylococcus aureus is a Gram-positive spherical bacterium about 1 µm in diameter that forms clusters. ...
Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared to baseline at six months Persistence of memory B and T cell immune responses at six months post second dose Pronounced SARS-CoV-2-specific T cell response to COVAXIN™ before and ...
Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. ...
Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data, including the possibility of ...
Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1). Recent preclinical studies further suggest ...
It is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic lung disease which results in progressive and irreversible decline in lung function. After completing IND-enabling studies, Insilico Medicine has initiated the microdose trial to begin characterizing the pharmacokinetic profile in humans. ...
(Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that data from in vitro studies supporting the early preclinical validation of PLA2R-Chimeric AutoAntibody Receptor T (CAART) cell candidates will be presented at ASN ...
Aresus Pharma GmbH, a company of DERMAGO Holding GmbH, announced today that the abstract “Inhibition of cell-proliferation and cell viability by Polyphenon E (Veregen) in cutaneous SCC cell lines” has been accepted as an e-poster short presentation at the 31st German Skin Cancer Congress. In the study, the authors around PD Dr. Eberle and Prof. Dr. Stockfleth were able to ...
The whole pipeline covers oncolytic virus engineering, construction, in vitro validation study, in vivo preclinical study, disease-specific oncolytic virotherapy development, and oncolytic virotherapy development for combination therapy with cancer immunotherapy. ...
Hanover, Germany, July 13, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced the results of extensive in vitro and in vivo studies demonstrating the therapeutic potential of H19 gene therapy to combat cardiac hypertrophy ...